Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation - University of Pavia, Pavia, Italy.
Br J Haematol. 2014 Apr;165(2):179-92. doi: 10.1111/bjh.12752. Epub 2014 Jan 30.
Our knowledge of the cellular and molecular mechanisms of platelet production has greatly expanded in recent years due to the opportunity to culture in vitro megakaryocytes and to create transgenic animals with specific genetic defects that interfere with platelet biogenesis. However, in vitro models do not reproduce the complexity of the bone marrow microenvironment where megakaryopoiesis takes place, and experience shows that what is seen in animals does not always happen in humans. So, these experimental models tell us what might happen in humans, but does not assure us that these events really occur. In contrast, inherited thrombocytopenias offer the unique opportunity to verify in humans the actual effects of abnormalities in specific molecules on platelet production. There are currently 20 genes whose defects are known to result in thrombocytopenia and, on this basis, this review tries to outline a model of megakaryopoiesis based on firm evidence. Inherited thrombocytopenias have not yet yielded all the information they can provide, because nearly half of patients have forms that do not fit with any known disorder. So, further investigation of inherited thrombocytopenias will advance not only the knowledge of human illnesses, but also our understanding of human platelet production.
近年来,由于能够体外培养巨核细胞和创建具有特定遗传缺陷的转基因动物,这些缺陷干扰血小板生成,我们对血小板生成的细胞和分子机制的认识有了很大的提高。然而,体外模型并不能再现骨髓微环境的复杂性,而经验表明,动物身上看到的情况并不总是在人类身上发生。因此,这些实验模型告诉我们在人类身上可能会发生什么,但并不能保证这些事件真的会发生。相比之下,遗传性血小板减少症为我们提供了一个独特的机会,可以在人类中验证特定分子异常对血小板生成的实际影响。目前已知有 20 个基因的缺陷会导致血小板减少症,在此基础上,本综述试图根据确凿的证据概述一个巨核细胞生成模型。遗传性血小板减少症尚未提供其所能提供的所有信息,因为近一半的患者存在与任何已知疾病都不相符的形式。因此,对遗传性血小板减少症的进一步研究不仅将推进我们对人类疾病的认识,也将增进我们对人类血小板生成的理解。